

University of Groningen

Erythropoietin in cardiac ischemia

Lipsic, Erik

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2006

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Lipsic, E. (2006). *Erythropoietin in cardiac ischemia*. [Thesis fully internal (DIV), University of Groningen]. [s.n.].

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Bibliography

Articles

1. **Lipšic E**, Balažovjeh I, Kosmálová V, Makaiová I, Dekrét J, Zanou DF. Epinephrine producing pheochromocytoma. Is the secretory pattern decisive for the clinical manifestation? *J Endocrinol Invest* 2004;27:691-4.
2. Van der Meer P, Voors AA, **Lipšic E**, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. *Eur Heart J* 2004;25(4):285-91.
3. Van der Meer P, Voors AA, **Lipšic E**, Smilde TDJ, van Gilst WH, van Veldhuisen DJ. Prognostic Value of Plasma Erythropoietin on mortality in Patients with Chronic Heart Failure. *J Am Coll Card* 2004;44(1):63-7.
4. **Lipšic E**, van der Meer P, Henning RH, Suurmeijer AJH, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/ Reperfusion. *J Cardiovasc Pharmacol* 2004;44(4):473-9.
5. Van der Meer P, **Lipšic E**, Henning RH, de Boer RA, Suurmeijer AJH, van Veldhuisen DJ, van Gilst WH. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. *Eur J Heart Fail* 2004;6(7):853-9.
6. **Lipšic E**, van der Horst ICC, Voors AA, van der Meer P, Nijsten MWN, van Veldhuisen DJ, van Gilst WH, Zijlstra F. Hemoglobin levels and 30-day mortality in patients after myocardial infarction. *Int J Cardiol* 2005;100(2):289-92.
7. Van der Meer P, **Lipšic E**, van Gilst WH, van Veldhuisen DJ. Erythropoietin: From hematopoiesis to cardioprotection. *Cardiovasc Drugs Ther.* 2005;19(1):7-8.
8. Van der Meer P, **Lipšic E**, Henning RH, Boddeus K, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. *J Am Coll Card* 2005;46(1):125-33.
9. **Lipšic E**, Asselbergs FW, van der Meer P, Tio RA, Voors AA, van Veldhuisen DJ, van Gilst WH, Zijlstra F. Anemia predicts cardiovascular events in patients with coronary artery disease. *Neth Heart J* 2005;13:208-12.
10. Van der Meer P, **Lipšic E**, Westenbrink BD, Voors AA, Schoemaker RG, Vellenga E, van Veldhuisen DJ, van Gilst WH. Serum of anemic heart failure patients inhibits proliferation of hematopoietic stem cells. *Circulation* 2005; 112:1743-7.
11. **Lipšic E**, Voors AA, van Veldhuisen DJ. Serum erythropoietin levels and infarct size. [letter]. *J Am Coll Card* 2006; 47(2):468-9.
12. **Lipšic E**, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AFM, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ. A single bolus of long-acting erythropoietin analogue darbepoetin in patients with an acute myocardial infarction: a randomized feasibility and safety study. *Cardiovasc Drugs Ther.* 2006; In press.

13. Van der Meer P, **Lipšić E**. Erythropoietin: repair of the failing heart. *J Am Coll Card* 2006; In press.
14. Langeveld B, **Lipšić E**, Roks AJM, van Gilst WH, Zijlstra F. Long-acting erythropoietin improves endothelial function after stent implantation without influencing neointima formation. *Submitted*.
15. Xu Y, Henning RH, **Lipšić E**, van Buiten A, van Gilst WH, Buikema H. Increased mesenteric myogenic constriction inversely relates to EDHF-mediated dilation in rats with experimental chronic heart failure. *Submitted*.
16. **Lipšić E**, van der Meer P, van der Harst P, Westenbrink BD, Koster J, du Marchie Sarvaas GJ, Voors AA, van Veldhuisen DJ, Schoemaker RG, van Gilst WH. Erythropoietin attenuates heart failure in a hematocrit independent manner. *Submitted*.
17. **Lipšić E**, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. *Submitted*.

Abstracts

1. **Lipšić E**, Kosmálová V, Makaiová I, Zanou DF, Dekrét J, Balažovjeh I. Epinephrine producing pheochromocytoma. *Am J of Hypert* 2001;14(4/2):251A.
2. Hirnerova E, Štvrtinová V, Ambrózy E, **Lipšić E**, Kosmálová V, Balažovjeh I. Association between hypertension and carotid atherosclerosis. *J of Hypert* 2001;19(Suppl 2):S268.
3. Van der Meer P, **Lipšić E**, de Boer RA, Henning RH, van Veldhuisen DJ, van Gilst WH. A Functional Erythropoietin Receptor in a Rat Heart is Linked to Anti- Apoptotic Effects. *J Am Coll Card* 2003;41(6-abstr suppl A):330A.
4. **Lipšić E**, van der Meer P, Suurmeijer AJH, Schoemaker RG, van Veldhuisen DJ, van Gilst WH, Henning RH. Erythropoietin protects against ischaemic damage in isolated rat heart. *Eur Heart J* 2003, 24(abstr suppl):477.
5. Van der Meer P, **Lipšić E**, Henning RH, de Boer RA, Suurmeijer AJ, van Veldhuisen DJ, van Gilst WH. Erythropoietin protects the heart against ischemia-reperfusion injury. *Circulation* 2003;108(17,abstr suppl):888.
6. Van der Meer P, Voors AA, **Lipšić E**, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. *J Am Coll Card* 2004;43(5,abstr suppl A):221A-222A.
7. **Lipšić E**, van der Meer P, de Boer RA, Suurmeijer AJH, van Gilst WH, van Veldhuisen DJ, Henning RH. Erythropoietin activates map kinase in isolated rat hearts. *N-S Arch Pharmacol* 2004;369(Suppl 1):26.
8. **Lipšić E**, van der Meer P, Henning RH, Suurmeijer AJH, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Therapeutic window for cardioprotective effect of erythropoietin during ischemia/reperfusion injury. *Eur Heart J* 2004, 25(abstr suppl):233.

9. Asselbergs FW, van der Meer P, Tio Ra, **Lipšić E**, van Veldhuisen DJ, van Gilst WH, Zijlstra F. Anemia predicts cardiovascular events in patients with coronary artery disease. *Eur Heart J* 2004, 25(abstr suppl):498.
10. Van der Meer P, Asselbergs FW, **Lipšić E**, Tio RA, Voors AA, van Veldhuisen DJ, Zijlstra F, van Gilst WH. Statin use is associated with lower EPO levels in patients with coronary artery disease. *Eur Heart J* 2004, 25(abstr suppl):603.
11. Van der Meer P, **Lipšić E**, Henning RH, Boddeus K, Suurmeijer AJH, Boomsma F, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin improves cardiac function in rats with heart failure after myocardial infarction. *N-S Arch Pharmacol* 2005;371(Suppl 1):R7.
12. **Lipšić E**, van der Meer P, Henning RH, Suurmeijer AJH, van Gilst WH, van Veldhuisen DJ, Schoemaker RG. Protective effect of erythropoietin on in-vivo ischemia/reperfusion injury in the heart. *N-S Arch Pharmacol* 2005;371(Suppl 1):R6.
13. Van der Meer P, **Lipšić E**, Henning RH, Boddeus K, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin increases capillary density and improves cardiac function in rats with heart failure after myocardial infarction. *J Am Coll Card* 2005;45(3, abstr suppl A):183A.
14. Van der Meer P, de la Porte PWB, **Lipšić E**, Lok DJ, Voors AA, van Veldhuisen DJ. Anemia in chronic heart failure: an inadequate erythropoietic response? *J Am Coll Card* 2005;45(3, abstr suppl A):178A.
15. Van der Meer P, **Lipšić E**, Henning RH, Boddeus KM, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin attenuates the development of heart failure and stimulates neovascularisation in a rat model of post MI-heart failure. *Eur Heart J* 2005, 26(Suppl 1):70.
16. Van der Meer P, **Lipšić E**, Westenbrink BD, Vellenga E, Schoemaker RG, van Veldhuisen DJ, Voors AA, van Gilst WH. Serum of anaemic heart failure patients inhibits haematopoiesis. *Eur Heart J* 2005, 26(Suppl 1):276.
17. **Lipšić E**, van der Meer P, Henning RH, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Darbepoetin treatment reduces infarct size and stimulates vascular growth after myocardial infarction. *Eur Heart J* 2005, 26(Suppl 1):650.
18. **Lipšić E**, van der Meer P, Voors AA, Westenbrink BD, van Gilst WH, Zijlstra F, van Veldhuisen DJ. A single bolus of long-acting erythropoietin analogue darbepoetin in patients with an acute myocardial infarction: A randomized feasibility and safety study. *Circulation* 2005; 112 (17):483.

